As technology develops, the conversation around weight loss medication has shifted from simple single-hormone "jabs" to sophisticated combination therapies.
At the forefront of this evolution is CagriSema, a weekly injection developed by Novo Nordisk.
While drugs like Wegovy (semaglutide) have already changed millions of lives, CagriSema aims to set a new benchmark by combining two different biological pathways.
Often described as next-gen Wegovy, this medication is currently making waves in late-stage clinical trials.
Here is everything you need to know about the development, results, and UK status of CagriSema.
Development: Two Hormones are Better Than One
CagriSema is a fixed-dose combination of two active ingredients.
By hitting two different receptors in the brain and gut simultaneously, it creates a synergistic effect that is more powerful than either drug used alone.
The Components:
- Semaglutide (2.4mg): The familiar GLP-1 receptor agonist found in Wegovy. It slows stomach emptying and signals "fullness" to the brain.
- Cagrilintide (2.4mg): A long-acting analogue of amylin. Amylin is a hormone co-secreted with insulin that regulates satiety (the feeling of being satisfied after a meal) and helps control blood sugar.
While GLP-1 primarily focuses on reducing hunger and slowing digestion, amylin works deeper on the "reward" pathways of the brain, helping to shut down cravings and emotional eating.
Together, they create what researchers call a "dual-agonism" that tackles appetite from two distinct biological angles.
Trial Results: The REDEFINE Program1
The clinical evidence for CagriSema comes from the massive REDEFINE trial program. The most recent data from early 2026 has provided a clear picture of its potency.
Weight Loss without Diabetes (REDEFINE 1)
In Phase 3 trials involving adults with obesity, CagriSema delivered some of the most impressive numbers to date:
- Total Weight Loss: Participants achieved an average weight loss of 22.7% to 23% over 68–84 weeks.
- Comparison: This was significantly higher than the weight loss seen with semaglutide alone (approx. 15–16%) in the same study.
- Metabolic Impact: Beyond weight, 87% of participants with pre-diabetes returned to normal blood sugar levels.
The Head-to-Head Battle (REDEFINE 4)
In a highly anticipated "clash of the titans" result released in February 2026, CagriSema was put directly against Eli Lilly’s Mounjaro (tirzepatide).
- The Result: CagriSema showed a 23% weight loss, while Mounjaro showed 25.5%. While CagriSema narrowly missed the "primary endpoint" of beating Mounjaro, it solidified its place as one of the top two most effective weight-loss medications ever created.
Side Effects: What to Expect
Because CagriSema involves two different hormones, the body has a bit more to process.
However, the safety profile remains very similar to the GLP-1 class we already know.
- Digestive Issues: Nausea is the most common side effect, affecting roughly 55% of users in trials. Vomiting and diarrhoea are also reported.
- Transient Nature: Most side effects are "mild to moderate" and occur during the initial weeks of treatment as the dose is escalated.
- Administration Site: Some users report redness or itching at the injection site, slightly more frequently than with semaglutide alone.
UK Status and Availability
As of March 2026, CagriSema is in the final regulatory stretch.
- Regulatory Submission: Novo Nordisk submitted CagriSema to the US FDA in late 2025 and to the UK’s MHRA shortly thereafter.
- Expected Approval: Medical authorities are expected to provide a decision by late 2026.
- UK Availability: If approved, CagriSema is expected to become available through private weight-loss clinics in mid-2027.
NHS availability will depend on a subsequent review by NICE, which usually takes place 6–12 months after a drug is licensed.
Summary: CagriSema vs. Wegovy vs. Mounjaro
| Feature | Wegovy (Semaglutide) | Mounjaro (Tirzepatide) | CagriSema |
| Mechanism | GLP-1 only | GLP-1 + GIP | GLP-1 + Amylin |
| Avg. Weight Loss | ~15% | ~22–25% | ~23% |
| Dosing | Weekly Injection | Weekly Injection | Weekly Injection |
| UK Status | Available | Available | Expected 2027 |
Conclusion
CagriSema represents a "stepping stone" toward a future where obesity is treated with multi-hormone precision.
By adding amylin to the mix, it offers a solution for those who may have plateaued on standard GLP-1s or who struggle specifically with intense cravings and "food noise."
While we are still about a year away from seeing it in UK pharmacies, the 2026 trial data confirms that CagriSema will be a formidable tool in the fight against metabolic disease.
In the meantime, Wegovy and Mounjaro remain the most popular options for medicated weight loss.
